{
    "clinical_study": {
        "@rank": "136238", 
        "acronym": "GnRHa trigger", 
        "arm_group": [
            {
                "arm_group_label": "Agonist trigger", 
                "arm_group_type": "Experimental", 
                "description": "Agonist trigger Buserelin 0,5 mg and Pregnyl (hCG)"
            }, 
            {
                "arm_group_label": "hCG", 
                "arm_group_type": "Active Comparator", 
                "description": "hCG trigger Pregnyl (hCG) and Progesterone and Estradiol"
            }
        ], 
        "brief_summary": {
            "textblock": "After hCG trigger a large amount of exogenous progesterone is used for luteal phase support\n      in many countries until 10th week of gestation. Instead we suggest the use of two small\n      doses of hCG after the trigger during the early luteal phase after GnRHa trigger, promoting\n      the endogenous progesterone production from the corpora lutea (CL)."
        }, 
        "brief_title": "The Exogenous Progesterone Free Luteal Phase After GnRHa Trigger - a Pilot Study in Normo-responder IVF Patients", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Infertility", 
        "condition_browse": {
            "mesh_term": "Infertility"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between 20 and 40\n\n          -  Normal menstrual cycles: 25-34 days\n\n          -  Oligomenorrhea/amenorrhea or polycystic syndrome (defined according to the Rotterdam\n             criteria 2004)\n\n          -  BMI >18 and <35 kg/m2\n\n        Exclusion Criteria:\n\n          -  Patients with >14 follicles on day of trigger\n\n          -  Previous hyperresponse with OHSS development\n\n          -  Previous low response (less than 3 oocytes on a high dose of FSH stimulation)\n\n          -  Endocrine disorders"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01980680", 
            "org_study_id": "Agonist5"
        }, 
        "intervention": [
            {
                "arm_group_label": "Agonist trigger", 
                "intervention_name": "hCG", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "hCG", 
                "intervention_name": "Progesterone and Estradiol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Estradiol", 
                "Polyestradiol phosphate", 
                "Progesterone", 
                "Estradiol valerate", 
                "Estradiol 3-benzoate", 
                "Estradiol 17 beta-cypionate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 9, 2014", 
        "number_of_arms": "2", 
        "official_title": "The Exogenous Progesterone Free Luteal Phase After GnRHa Trigger - a Randomized Controlled Pilot Study in Normo-responder IVF Patients", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Denmark: Danish Health and Medicines Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Ongoing pregnancy rate per patient", 
            "safety_issue": "No", 
            "time_frame": "10th week of gestation."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980680"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Regionshospitalet Viborg, Skive", 
            "investigator_full_name": "Peter Humaidan", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Regionshospitalet Viborg, Skive", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peter Humaidan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}